Used in research and development for Alzheimer’s disease, this antibody targets soluble amyloid-beta peptides in the brain, aiming to reduce plaque buildup linked to cognitive decline. It has been investigated in clinical trials to assess its potential to slow disease progression in early-stage patients. The antibody serves as a reference standard in immunoassays and therapeutic development, supporting the evaluation of drug efficacy and biomarker measurement. Its high specificity makes it valuable for detecting amyloid-beta in biological samples and validating new diagnostic tools.